Compare
Rockwell Medical, Inc. vs Kura Oncology, Inc. vs Spero Therapeutics, Inc. vs Assembly Biosciences, Inc.
| Latest fiscal year | Rockwell Medical, Inc. RMTI | Kura Oncology, Inc. KURA | Spero Therapeutics, Inc. SPRO | Assembly Biosciences, Inc. ASMB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $69.26M | $67.48M | $66.80M | $72.30M |
| Revenue growth (YoY) | -31.8% | +25.2% | +39.2% | +153.5% |
| Gross margin | 16.9% | n/a | n/a | n/a |
| Operating margin | -6.8% | -449.9% | 9.5% | -16.8% |
| Net margin | -7.7% | -412.9% | 12.8% | -8.5% |
| Net income | -$5.31M | -$278.67M | $8.57M | -$6.12M |
| EPS (Diluted) | -$0.15 | -$3.18 | $0.15 | -$0.55 |
| Operating cash flow | -$659.0K | -$64.06M | -$12.62M | -$41.09M |
| Free cash flow | -$1.20M | -$70.70M | n/a | -$41.16M |
| Cash & equivalents | $10.71M | $149.10M | $40.27M | $58.45M |
| Total assets | $57.15M | $738.36M | $68.92M | $257.59M |
| Total liabilities | $20.16M | $564.23M | $9.90M | $50.84M |
| Shareholders' equity | $36.98M | $174.13M | $59.02M | $206.75M |
| Return on year-end equity | -14.4% | -160.0% | 14.5% | -3.0% |
| Shares outstanding | 39.41M | 87.86M | 56.41M | 15.86M |
Revenue, most recent five fiscal years
| Fiscal year | Rockwell Medical, Inc. | Kura Oncology, Inc. | Spero Therapeutics, Inc. | Assembly Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $69.26M Ended 2025-12-31 | $67.48M Ended 2025-12-31 | $66.80M Ended 2025-12-31 | $72.30M Ended 2025-12-31 |
| 1 year earlier | $101.49M Ended 2024-12-31 | $53.88M Ended 2024-12-31 | $47.98M Ended 2024-12-31 | $28.52M Ended 2024-12-31 |
| 2 years earlier | $83.61M Ended 2023-12-31 | $0 Ended 2023-12-31 | $103.78M Ended 2023-12-31 | $7.16M Ended 2023-12-31 |
| 3 years earlier | $72.81M Ended 2022-12-31 | n/a | $53.51M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $61.93M Ended 2021-12-31 | n/a | $18.26M Ended 2021-12-31 | $6.25M Ended 2021-12-31 |